2 June 2016
PACIFIC EDGE BOARD CHANGES ANNOUNCED
Cancer diagnostics company, Pacific Edge Limited (NZX:PEB), has today
announced some changes to its Board, including the appointment of Chris
Gallaher as an Independent Director, effective from 1st July 2016.
Chris is a senior corporate executive with a background in financial and
general management and has had international experience in both public and
private companies. He is the recently retired Group Chief Financial Officer
for Fulton Hogan and has held senior executive and CEO roles with Vector,
Village Roadshow, Carter Holt Harvey and was a partner in the chartered
accounting firm Arthur Young with whom he started his career in Dunedin.
Chairman of Pacific Edge, Chris Swann, said: "Chris brings significant
financial and risk management expertise to the company and will be a welcome
addition to the Board. We have undertaken a review of the skills and
expertise required as Pacific Edge continues to progress its
commercialisation in the US and other targeted markets. Chris''s appointment,
coupled with the recent appointment of US-based David Levison, brings further
strength to the Board as we continue to help shape Pacific Edge''s future."
Current Board member, Charles Sitch, has advised the Board of his intention
to retire from the Board, effective immediately, due to increasing
commitments in Australia. In addition, Chris Swann has announced his decision
to retire at the next annual shareholders'' meeting on 25 August 2016 after
more than a decade on the Board. Chris will retire by rotation and will not
offer himself up for re-election.
Chris said: "It has been a rewarding and at times, challenging journey for
Pacific Edge over the last ten years as the company has successfully
transitioned from a research-based start up to a commercial entity. I am
confident that the company is in good shape going forward, with a strong
Board and management team."
About Chris Gallaher
Chris is a senior executive with extensive financial and general management
expertise. A New Zealander based in Melbourne, his career has been spent
within large international companies in a range of financial and senior
management roles, where he worked closely with company Boards and Audit
Committees. He also serves on the Board of The Good Shepherd New Zealand and
the investment committee of property development company, Substancia Pty Ltd
. Chris is a Chartered Accountant and holds a BCom from Otago University and
is a member of the Australian Institute of Company Directors.
ENDS
For more information contact:
David Darling
Executive Director and CEO
Pacific Edge Ltd
P: +64 (3) 479 5800
OVERVIEW www.pacificedge.co.nz www.pacificedgedx.com
Pacific Edge Limited (NZX: PEB) is a New Zealand publicly listed, cancer
diagnostic company specialising in the discovery and commercialisation of
diagnostic and prognostic tests for better detection and management of
cancer. The company is developing and commercialising its range of Cxbladder
bladder cancer tests globally through its wholly owned central laboratories
in New Zealand and the USA. The company''s products have been tested and
validated in international multi-centre clinical studies. Pacific Edge has
three proprietary, novel, accurate, molecular diagnostic products in-market
providing actionable results, and better detection and management of
urothelial cancer. Cxbladder Detect is available through the company''s
dedicated CLIA certified laboratories for customers in New Zealand, Australia
and the USA. Cxbladder Triage is available in New Zealand and Australia.
Cxbladder Monitor launched in New Zealand in December 2015 and is anticipated
being available in the US in 2016.
ABOUT Cxbladder Triage www.cxbladder.com
Cxbladder Triage combines the power of the genomic biomarkers with additional
phenotypic and clinical risk factors to accurately identify patients with
haematuria who have a low probability of bladder cancer and may not require a
more extensive urological evaluation. Cxbladder Triage is a tool for use by
clinicians and physicians in primary evaluation of patients with hematuria
and is intended to reduce the need for an expensive and invasive work-up in
patients who have a low probability of having urothelial carcinoma.
ABOUT Cxbladder Detect www.cxbladder.com
Cxbladder Detect enables the non-invasive detection of bladder and other
urinary tract cancers from a small volume of a patients'' urine. Cxbladder
Detect was launched in 2013 in the USA and is commercially available in New
Zealand, Australia and the USA as a Laboratory Developed Test (LDT) from the
company''s CLIA certified laboratories. Cxbladder Detect provides physicians
and clinicians with a quick, cost effective and accurate measure of the
presence of the cancer as an effective adjunct to cystoscopy.
ABOUT Cxbladder Monitor www.cxbladder.com
Cxbladder Monitor, the third test in the Cxbladder portfolio for urologists,
is a proprietary, non-invasive, molecular diagnostic test that combines
genomic biomarkers measured from a small quantity of a patient''s urine, with
patient specific clinical factors to better monitor bladder cancer patients
for recurrence. Bladder cancer has a recurrence rate of 50-80% and requires
life-long surveillance. Cxbladder Monitor accurately identifies patients with
a prior history of urothelial cancer (UC) whose Cxbladder Monitor score shows
that they have a low probability of recurrent urothelial carcinoma. Cxbladder
Monitor is designed to be used as the preferred adjunct test to cystoscopy in
the management of patients for ongoing evaluation of recurrent bladder
cancer.
Refer to www.cxbladder.com for more information.
End CA:00283427 For:PEB Type:DIRECTOR Time:2016-06-02 11:52:40